bromperidol decanoate: used in the long-term treatment of psychotic disorders [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 156321 |
| CHEMBL ID | 2106135 |
| SCHEMBL ID | 121019 |
| MeSH ID | M0207267 |
| Synonym |
|---|
| bromperidol decanoate |
| 75067-66-2 |
| bromperidol decanoate (usan) |
| D02626 |
| [4-(4-bromophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl] decanoate |
| 4-(4-bromophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl decanoate |
| 4-(4-(p-bromophenyl)-4-hydroxypiperidinol)-4'-fluorobutyrophenone decanoate (ester) |
| r-46,541 |
| einecs 278-065-1 |
| decanoic acid, 4-(4-bromophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl ester |
| r 46541 |
| r 46,541 |
| unii-73lg72m4lv |
| 73lg72m4lv , |
| bromperidol decanoate [usan:ban] |
| r-46541 |
| CHEMBL2106135 |
| 4-(4-(p-bromophenyl)-4-hydroxypiperidinol)-4'-fluorobutyrophenone decanoate |
| bromperidol decanoate [who-dd] |
| bromperidol decanoate [ep impurity] |
| bromperidol decanoate [usp-rs] |
| bromperidol decanoate [usan] |
| bromperidol decanoate [mart.] |
| bromperidol decanoate [ep monograph] |
| decanoic acid,4-(4-bromophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl ester |
| SCHEMBL121019 |
| DTXSID30226039 |
| bromperidoldecanoat |
| AKOS027276161 |
| Q27266190 |
| 4-(4-bromophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)piperidin-4-yl decanoate |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The recommended initial dosage was 150 mg bromperidol (one 3 ml ampoule), and this did not in fact have to be increased during the trial." | ( [Bromperidol decanoate in the residual phase of schizophrenia]. Canova, L; Cocconcelli, C; Faravelli, C; Marchetti, FP; Mariani, G; Rapisarda, V; Smeraldi, E, 1996) | 1.2 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 4 (66.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||